Is there any value in that the company has not asked for any more shares, and that the S3 includes a total dollar amount of $100 million but no specifice share/warrant price terms. I guess, I am asking that if we only have ?150 million shares available to issue, could another entity or partner take a stake at say $1 a share to generate $100 mil for cytodyn to pursue trials and thereby take equity in the company. Usually partners buy percentage rights to the molecule for an uprfront and milestone payments, but could it be structured this way to pop the share price.

I might just be wearing rose colored glasses here.